Chemical Engineering @ChemengFiles.Com

The results of a trial lasting eight years with more than 130,000 women, published today in The New England Journal of Medicine (NEJM), show that in environments with few resources, a single cycle of HPV testing significantly reduces the numbers of advanced cervical cancer and related deaths, compared with the cytology smear and visual inspection with acetic acid (VIA). In the trial test was used Digene HPV Qiagen, which detects the types of human papilloma virus that cause high-risk cervical cancer.

"The implications of the findings of this test are immediate and global: the international experts in the prevention of cervical cancer must now adapt the HPV test to achieve widespread implementation," - drafted doctors Sholom Wacholder and Mark Schiffman of the National Institute U.S. Cancer in an article that is attached to the study in the NEJM. "The great promise of the Indian study represents an estimable challenge at the global level to implement the best strategies tailored to each region, which efficiently save millions of lives in coming years."

Following this study and critical over the next five years, Qiagen will donate one million tests for HPV, with an estimated total value exceeding $ 30 million (depending on the price list of EE. UU.) Inside your expanded global access program to bring women in developing countries the technologies of the highest quality to detect cervical cancer. Nearly 300,000 women die each year because of cervical cancer, with 80% of these deaths in developing countries. Qiagen of the commitment to expand access to HPV testing includes:

- Programs donation HPV testing in conjunction with the main public health institutions and health NGOs

- Development of next generation technologies for HPV, including HPV testing care, designed especially for developing countries with limited resources

- Initiatives to tiered pricing for low-income countries